Effect of Ghrelin on mortality and cardiovascular outcomes in experimental rat and mice models of heart failure

A systematic review and meta-analysis

Mahalaqua Nazli Khatib, Anuraj Shankar, Richard Kirubakaran, Kingsley Agho, Padam Simkhada, Shilpa Gaidhane, Deepak Saxena, B. Unnikrishnan, Dilip Gode, Abhay Gaidhane, Syed Quazi Zahiruddin

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Heart failure (HF) continues to be a challenging condition in terms of prevention and management of the disease. Studies have demonstrated various cardio-protective effects of Ghrelin. The aim of the study is to determine the effect of Ghrelin on mortality and cardiac function in experimental rats/mice models of HF. Methods: Data sources: PUBMED, Scopus. We searched the Digital Dissertations and conference proceedings on Web of Science. Search methods: We systematically searched for all controlled trials (upto November 2014) which assessed the effects of Ghrelin (irrespective of dose, form, frequency, duration and route of administration) on mortality and cardiac function in rats/ mice models of HF. Ghrelin administration irrespective of dose, form, frequency, duration and route of administration. Data collection and analysis: Two authors independently assessed each abstract for eligibility and extracted data on characteristics of the experimental model used, intervention and outcome measures. We assessed the methodological quality by SYRCLE's risk of bias tool for all studies and the quality of evidence by GRADEpro. We performed meta-analysis using RevMan 5.3. Results: A total of 325 animals (rats and mice) were analyzed across seven studies. The meta-analysis revealed that the mortality in Ghrelin group was 31.1% and in control group was 40% (RR 0.83, 95% CI 0.46 to 1.47) i.e Ghrelin group had 68 fewer deaths per 1000 (from 216 fewer to 188 more) as compared to the control group. The meta-analysis reveals that the heart rate in rats/mice on Ghrelin was higher (MD 13.11, 95% CI 1.14 to 25.08, P=0.66) while the mean arterial blood pressure (MD -1.38, 95% CI -5.16 to 2.41, P=0.48) and left ventricular end diastolic pressure (MD -2.45, 95% CI -4.46 to -0.43, P=0.02) were lower as compared to the those on placebo. There were insignificant changes in cardiac output (SMD 0.28, 95% CI -0.24 to 0.80, P=0.29) and left ventricular end systolic pressure (MD 1.48, 95% CI -3.86 to 6.82, P=0.59). Conclusions: The existing data provides evidence to suggest that Ghrelin may lower the risk of mortality and improve cardiovascular outcomes. However; the quality of evidence as assessed by GRADEpro is low to very low. Clinical judgments to administer Ghrelin to patients with HF must be made on better designed animal studies.

Original languageEnglish
Article numbere0126697
JournalPLoS One
Volume10
Issue number5
DOIs
Publication statusPublished - 27-05-2015

Fingerprint

ghrelin
Ghrelin
systematic review
heart failure
meta-analysis
Meta-Analysis
Rats
Heart Failure
animal models
Mortality
cardiac output
Arterial Pressure
Animals
Blood Pressure
cardioprotective effect
Control Groups
duration
Surface mount technology
Information Storage and Retrieval
rats

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Khatib, M. N., Shankar, A., Kirubakaran, R., Agho, K., Simkhada, P., Gaidhane, S., ... Zahiruddin, S. Q. (2015). Effect of Ghrelin on mortality and cardiovascular outcomes in experimental rat and mice models of heart failure: A systematic review and meta-analysis. PLoS One, 10(5), [e0126697]. https://doi.org/10.1371/journal.pone.0126697
Khatib, Mahalaqua Nazli ; Shankar, Anuraj ; Kirubakaran, Richard ; Agho, Kingsley ; Simkhada, Padam ; Gaidhane, Shilpa ; Saxena, Deepak ; Unnikrishnan, B. ; Gode, Dilip ; Gaidhane, Abhay ; Zahiruddin, Syed Quazi. / Effect of Ghrelin on mortality and cardiovascular outcomes in experimental rat and mice models of heart failure : A systematic review and meta-analysis. In: PLoS One. 2015 ; Vol. 10, No. 5.
@article{13d034e2a6b8467baf60da2892c60c77,
title = "Effect of Ghrelin on mortality and cardiovascular outcomes in experimental rat and mice models of heart failure: A systematic review and meta-analysis",
abstract = "Background: Heart failure (HF) continues to be a challenging condition in terms of prevention and management of the disease. Studies have demonstrated various cardio-protective effects of Ghrelin. The aim of the study is to determine the effect of Ghrelin on mortality and cardiac function in experimental rats/mice models of HF. Methods: Data sources: PUBMED, Scopus. We searched the Digital Dissertations and conference proceedings on Web of Science. Search methods: We systematically searched for all controlled trials (upto November 2014) which assessed the effects of Ghrelin (irrespective of dose, form, frequency, duration and route of administration) on mortality and cardiac function in rats/ mice models of HF. Ghrelin administration irrespective of dose, form, frequency, duration and route of administration. Data collection and analysis: Two authors independently assessed each abstract for eligibility and extracted data on characteristics of the experimental model used, intervention and outcome measures. We assessed the methodological quality by SYRCLE's risk of bias tool for all studies and the quality of evidence by GRADEpro. We performed meta-analysis using RevMan 5.3. Results: A total of 325 animals (rats and mice) were analyzed across seven studies. The meta-analysis revealed that the mortality in Ghrelin group was 31.1{\%} and in control group was 40{\%} (RR 0.83, 95{\%} CI 0.46 to 1.47) i.e Ghrelin group had 68 fewer deaths per 1000 (from 216 fewer to 188 more) as compared to the control group. The meta-analysis reveals that the heart rate in rats/mice on Ghrelin was higher (MD 13.11, 95{\%} CI 1.14 to 25.08, P=0.66) while the mean arterial blood pressure (MD -1.38, 95{\%} CI -5.16 to 2.41, P=0.48) and left ventricular end diastolic pressure (MD -2.45, 95{\%} CI -4.46 to -0.43, P=0.02) were lower as compared to the those on placebo. There were insignificant changes in cardiac output (SMD 0.28, 95{\%} CI -0.24 to 0.80, P=0.29) and left ventricular end systolic pressure (MD 1.48, 95{\%} CI -3.86 to 6.82, P=0.59). Conclusions: The existing data provides evidence to suggest that Ghrelin may lower the risk of mortality and improve cardiovascular outcomes. However; the quality of evidence as assessed by GRADEpro is low to very low. Clinical judgments to administer Ghrelin to patients with HF must be made on better designed animal studies.",
author = "Khatib, {Mahalaqua Nazli} and Anuraj Shankar and Richard Kirubakaran and Kingsley Agho and Padam Simkhada and Shilpa Gaidhane and Deepak Saxena and B. Unnikrishnan and Dilip Gode and Abhay Gaidhane and Zahiruddin, {Syed Quazi}",
year = "2015",
month = "5",
day = "27",
doi = "10.1371/journal.pone.0126697",
language = "English",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

Khatib, MN, Shankar, A, Kirubakaran, R, Agho, K, Simkhada, P, Gaidhane, S, Saxena, D, Unnikrishnan, B, Gode, D, Gaidhane, A & Zahiruddin, SQ 2015, 'Effect of Ghrelin on mortality and cardiovascular outcomes in experimental rat and mice models of heart failure: A systematic review and meta-analysis', PLoS One, vol. 10, no. 5, e0126697. https://doi.org/10.1371/journal.pone.0126697

Effect of Ghrelin on mortality and cardiovascular outcomes in experimental rat and mice models of heart failure : A systematic review and meta-analysis. / Khatib, Mahalaqua Nazli; Shankar, Anuraj; Kirubakaran, Richard; Agho, Kingsley; Simkhada, Padam; Gaidhane, Shilpa; Saxena, Deepak; Unnikrishnan, B.; Gode, Dilip; Gaidhane, Abhay; Zahiruddin, Syed Quazi.

In: PLoS One, Vol. 10, No. 5, e0126697, 27.05.2015.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of Ghrelin on mortality and cardiovascular outcomes in experimental rat and mice models of heart failure

T2 - A systematic review and meta-analysis

AU - Khatib, Mahalaqua Nazli

AU - Shankar, Anuraj

AU - Kirubakaran, Richard

AU - Agho, Kingsley

AU - Simkhada, Padam

AU - Gaidhane, Shilpa

AU - Saxena, Deepak

AU - Unnikrishnan, B.

AU - Gode, Dilip

AU - Gaidhane, Abhay

AU - Zahiruddin, Syed Quazi

PY - 2015/5/27

Y1 - 2015/5/27

N2 - Background: Heart failure (HF) continues to be a challenging condition in terms of prevention and management of the disease. Studies have demonstrated various cardio-protective effects of Ghrelin. The aim of the study is to determine the effect of Ghrelin on mortality and cardiac function in experimental rats/mice models of HF. Methods: Data sources: PUBMED, Scopus. We searched the Digital Dissertations and conference proceedings on Web of Science. Search methods: We systematically searched for all controlled trials (upto November 2014) which assessed the effects of Ghrelin (irrespective of dose, form, frequency, duration and route of administration) on mortality and cardiac function in rats/ mice models of HF. Ghrelin administration irrespective of dose, form, frequency, duration and route of administration. Data collection and analysis: Two authors independently assessed each abstract for eligibility and extracted data on characteristics of the experimental model used, intervention and outcome measures. We assessed the methodological quality by SYRCLE's risk of bias tool for all studies and the quality of evidence by GRADEpro. We performed meta-analysis using RevMan 5.3. Results: A total of 325 animals (rats and mice) were analyzed across seven studies. The meta-analysis revealed that the mortality in Ghrelin group was 31.1% and in control group was 40% (RR 0.83, 95% CI 0.46 to 1.47) i.e Ghrelin group had 68 fewer deaths per 1000 (from 216 fewer to 188 more) as compared to the control group. The meta-analysis reveals that the heart rate in rats/mice on Ghrelin was higher (MD 13.11, 95% CI 1.14 to 25.08, P=0.66) while the mean arterial blood pressure (MD -1.38, 95% CI -5.16 to 2.41, P=0.48) and left ventricular end diastolic pressure (MD -2.45, 95% CI -4.46 to -0.43, P=0.02) were lower as compared to the those on placebo. There were insignificant changes in cardiac output (SMD 0.28, 95% CI -0.24 to 0.80, P=0.29) and left ventricular end systolic pressure (MD 1.48, 95% CI -3.86 to 6.82, P=0.59). Conclusions: The existing data provides evidence to suggest that Ghrelin may lower the risk of mortality and improve cardiovascular outcomes. However; the quality of evidence as assessed by GRADEpro is low to very low. Clinical judgments to administer Ghrelin to patients with HF must be made on better designed animal studies.

AB - Background: Heart failure (HF) continues to be a challenging condition in terms of prevention and management of the disease. Studies have demonstrated various cardio-protective effects of Ghrelin. The aim of the study is to determine the effect of Ghrelin on mortality and cardiac function in experimental rats/mice models of HF. Methods: Data sources: PUBMED, Scopus. We searched the Digital Dissertations and conference proceedings on Web of Science. Search methods: We systematically searched for all controlled trials (upto November 2014) which assessed the effects of Ghrelin (irrespective of dose, form, frequency, duration and route of administration) on mortality and cardiac function in rats/ mice models of HF. Ghrelin administration irrespective of dose, form, frequency, duration and route of administration. Data collection and analysis: Two authors independently assessed each abstract for eligibility and extracted data on characteristics of the experimental model used, intervention and outcome measures. We assessed the methodological quality by SYRCLE's risk of bias tool for all studies and the quality of evidence by GRADEpro. We performed meta-analysis using RevMan 5.3. Results: A total of 325 animals (rats and mice) were analyzed across seven studies. The meta-analysis revealed that the mortality in Ghrelin group was 31.1% and in control group was 40% (RR 0.83, 95% CI 0.46 to 1.47) i.e Ghrelin group had 68 fewer deaths per 1000 (from 216 fewer to 188 more) as compared to the control group. The meta-analysis reveals that the heart rate in rats/mice on Ghrelin was higher (MD 13.11, 95% CI 1.14 to 25.08, P=0.66) while the mean arterial blood pressure (MD -1.38, 95% CI -5.16 to 2.41, P=0.48) and left ventricular end diastolic pressure (MD -2.45, 95% CI -4.46 to -0.43, P=0.02) were lower as compared to the those on placebo. There were insignificant changes in cardiac output (SMD 0.28, 95% CI -0.24 to 0.80, P=0.29) and left ventricular end systolic pressure (MD 1.48, 95% CI -3.86 to 6.82, P=0.59). Conclusions: The existing data provides evidence to suggest that Ghrelin may lower the risk of mortality and improve cardiovascular outcomes. However; the quality of evidence as assessed by GRADEpro is low to very low. Clinical judgments to administer Ghrelin to patients with HF must be made on better designed animal studies.

UR - http://www.scopus.com/inward/record.url?scp=84939551585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939551585&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0126697

DO - 10.1371/journal.pone.0126697

M3 - Article

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 5

M1 - e0126697

ER -